Intranet_FF9900-transparent
Login
Linkedin
Twitter
Envelope
  • About EUnetHTA
    • History of EUnetHTA
      • JA 3 (2016-2020)
      • JA 2 Archive (2012-2015)
      • JA 1 Archive (2010-2012)
      • EUnetHTA Collaboration (2009)
      • EUnetHTA Project (2006-2008)
    • EUnetHTA Network
    • Organisation
      • The Executive Board
      • The Secretariat
    • Vision, Mission, and Values
    • EUnetHTA and the HTA Network
    • EUnetHTA Magazine
      • Winter 2020
      • Autumn 2019
      • Summer 2019
      • Winter 2018-2019
      • Autumn 2018
      • Summer 2018
      • Spring 2018
      • Winter 2017 – 2018
      • Autumn 2017
    • Acronyms
  • Covid-19 Response
    • Diagnostics
    • Treatments
    • Useful Links
  • Services
    • Assessment Submission
    • Early Dialogues
      • Early Dialogues for Pharmaceutical Products
      • Early Dialogues for Medical Devices
    • PLEG
  • Assessments
    • EUnetHTA Prioritisation List (EPL) – Pharmaceuticals
    • EUnetHTA Prioritisation List (EPL) – Other Technologies
    • Assessments REA (2016 – 2021)
    • Topic Identification, Selection and Prioritisation
    • National Uptake and Case Studies
    • PICO FAQ
    • Assessment Archive (2006 – 2015)
    • Assessment FAQ
  • Tools
    • HTA Core Model®
    • Methodology
    • REQueST® Tool
    • POP Database
    • EVIDENT Database
    • Declaration of Interest (DOI)
    • Submission Template for Pharma and Med. Devices
    • Companion Guide
    • Tools Archive
      • HTA Adaptation Toolkit
  • Get Involved
    • Patients
    • Industry
    • Health Care Professionals
    • Payers
    • Regulators
    • Events
      • 2021 EUnetHTA Forum
      • 2020 EUnetHTA Forum
      • 2019 EUnetHTA Forum
      • 2018 EUnetHTA Forum
      • 2017 EUnetHTA Forum
      • Upcoming Events
Menu
  • About EUnetHTA
    • History of EUnetHTA
      • JA 3 (2016-2020)
      • JA 2 Archive (2012-2015)
      • JA 1 Archive (2010-2012)
      • EUnetHTA Collaboration (2009)
      • EUnetHTA Project (2006-2008)
    • EUnetHTA Network
    • Organisation
      • The Executive Board
      • The Secretariat
    • Vision, Mission, and Values
    • EUnetHTA and the HTA Network
    • EUnetHTA Magazine
      • Winter 2020
      • Autumn 2019
      • Summer 2019
      • Winter 2018-2019
      • Autumn 2018
      • Summer 2018
      • Spring 2018
      • Winter 2017 – 2018
      • Autumn 2017
    • Acronyms
  • Covid-19 Response
    • Diagnostics
    • Treatments
    • Useful Links
  • Services
    • Assessment Submission
    • Early Dialogues
      • Early Dialogues for Pharmaceutical Products
      • Early Dialogues for Medical Devices
    • PLEG
  • Assessments
    • EUnetHTA Prioritisation List (EPL) – Pharmaceuticals
    • EUnetHTA Prioritisation List (EPL) – Other Technologies
    • Assessments REA (2016 – 2021)
    • Topic Identification, Selection and Prioritisation
    • National Uptake and Case Studies
    • PICO FAQ
    • Assessment Archive (2006 – 2015)
    • Assessment FAQ
  • Tools
    • HTA Core Model®
    • Methodology
    • REQueST® Tool
    • POP Database
    • EVIDENT Database
    • Declaration of Interest (DOI)
    • Submission Template for Pharma and Med. Devices
    • Companion Guide
    • Tools Archive
      • HTA Adaptation Toolkit
  • Get Involved
    • Patients
    • Industry
    • Health Care Professionals
    • Payers
    • Regulators
    • Events
      • 2021 EUnetHTA Forum
      • 2020 EUnetHTA Forum
      • 2019 EUnetHTA Forum
      • 2018 EUnetHTA Forum
      • 2017 EUnetHTA Forum
      • Upcoming Events

THL => FinCCHTA

Home
THL => FinCCHTA

See Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)

National Institute for Health and Welfare

Mannerheimintie 166A,

Helsinki

Finland

Tel.:+358 29 524 6000

Email: info@thl.fi

http://www.thl.fi/

EUnetHTA involvement

As Lead Partner

  • EUnetHTA Joint Action 2 (2012-15)
    • JA2 WP8 – Maintenance of HTA Core Model infrastructure to support shared production and sharing of HTA information
  • EUnetHTA Joint Action (2010-12)
    • JA WP4 – Core HTA

As Associated Partner

  • EUnetHTA Joint Action 2 (2012-15)
    • JA2 WP1 – Coordination
    • JA2 WP2 – Dissemination
    • JA2 WP4 – Testing collaborative production of HTA information for national adaptation and reporting
    • JA2 WP5 – Applying the HTA Core Model for Rapid Assessment for national adaptation and reporting
    • JA2 WP6 – Information Management Infrastructure and Services (IMIS)
  • EUnetHTA Joint Action (2010-12)
    • JA WP1 – Coordination
    • JA WP4 – Core HTA
    • JA WP5 – Relative Effectiveness Assessment of Pharmaceuticals
    • JA WP6 – Information Management System
    • JA WP7 – New Technologies
    • JA WP8 – Strategy and Business Model Development
  • EUnetHTA Joint Action 3 (2016-20)
    • Work Package 7 – National implementation and impact
    • Work Package 4 – Joint Production
    • Work Package 5 – Life cycle approach to improve Evidence Generation
    • Work Package 6 – Quality Management, Scientific Guidance and Tools

OUR NETWORK

  • EUnetHTA Network
  • JA 3 (2016-2021)
  • JA 2 Archive (2012-2015)
  • JA 1 Archive (2010-2012)
  • EUnetHTA Collaboration (2009)
  • EUnetHTA Project (2006-2008)
Menu
  • EUnetHTA Network
  • JA 3 (2016-2021)
  • JA 2 Archive (2012-2015)
  • JA 1 Archive (2010-2012)
  • EUnetHTA Collaboration (2009)
  • EUnetHTA Project (2006-2008)

CAREERS

  • Work with EUnetHTA
Menu
  • Work with EUnetHTA

HELP

eunethta@zinl.nl

CONTACT US

  • Media and Press
  • Disclaimer
  • Reusing our content
  • Terms of use
  • Privacy Policy
Menu
  • Media and Press
  • Disclaimer
  • Reusing our content
  • Terms of use
  • Privacy Policy

This website is part of joint action ‘724130 / EUnetHTA JA3’ which has received funding from the European Union’s Health Programme (2014-2020).

©2021 EUnetHTA All rights reserved.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.
Accept and Close